Product information
From Health Canada
No match found
No other product was found from this company.
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Cancelled Post Market
Current status date:
2021-12-22
Original market date: See footnote 1
2007-10-23
Lot number: See footnote 2
CDFTW
Expiry date: See footnote 2
2023-11-30
Product name:
ATRIPLA
DIN:
02300699
Product Monograph/Veterinary Labelling:
Date:
2020-02-12
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
GILEAD SCIENCES, LLC
333 Lakeside Drive
Foster City
California
United States
94404
Class:
Human
Dosage form(s):
Tablet
Route(s) of administration:
Oral
Number of active ingredient(s):
3
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
08:18.08.16 , 08:18.08.20
Anatomical Therapeutic Chemical (ATC): See footnote 4
J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ
Active ingredient group (AIG) number:See footnote5
0352327001
Active ingredient(s) | Strength |
---|---|
EFAVIRENZ | 600 MG |
EMTRICITABINE | 200 MG |
TENOFOVIR DISOPROXIL FUMARATE | 300 MG |